scholarly journals Impairment and restrictions in possibly benign multiple sclerosis

2019 ◽  
Vol 9 (4) ◽  
pp. e01259 ◽  
Author(s):  
Laura Melanie Schaefer ◽  
Jana Poettgen ◽  
Anja Fischer ◽  
Stefan Gold ◽  
Jan‐Patrick Stellmann ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Benign Multiple Sclerosis

Different neuroinflammatory gene expression profiles in highly active and benign multiple sclerosis

2021 ◽  
pp. 577650
Author(s):  
Maria Ivanova ◽  
Anastasiya Voronkova ◽  
Vladimir Sukhorukov ◽  
Maria Zakharova
Keyword(s):  
Gene Expression ◽  
Multiple Sclerosis ◽  
Expression Profiles ◽  
Gene Expression Profiles ◽  
Highly Active ◽  
Benign Multiple Sclerosis

‘Clinically definite benign multiple sclerosis’, an unwarranted conceptual hodgepodge: evidence from a 30-year observational study

2012 ◽  
Vol 19 (4) ◽  
pp. 458-465 ◽  
Author(s):  
E Leray ◽  
M Coustans ◽  
E Le Page ◽  
J Yaouanq ◽  
J Oger ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Observational Study ◽  
Medical Treatments ◽  
Clinical Onset ◽  
Disability Status ◽  
Relapsing Remitting ◽  
Long Term Follow Up ◽  
Benign Multiple Sclerosis ◽  
New Biomarkers

Background: Benign multiple sclerosis (BMS) is a controversial concept which is still debated. However identification of this kind of patients is crucial to prevent them from unnecessary exposure to aggressive and/or long term medical treatments. Objectives: To assess two definitions of ‘clinically definite benign multiple sclerosis’ (CDBMS) using long-term follow-up data, and to look for prognostic factors of CDBMS. Methods: In 874 patients with definite relapsing–remitting MS, followed up for at least 10 years, disability was assessed using the Disability Status Scale (DSS). CDBMS was defined by either DSS score≤2 (CDBMS1 group) or DSS score≤ 3 (CDBMS2 group) at 10 years. We estimated the proportion of patients who were still benign at 20 and 30 years after clinical onset. Results: CDBMS frequency estimates were 57.7% and 73.9% when using CDBMS1 and CDBMS2 definitions, respectively. In the CDBMS1 group, only 41.7% (105/252) of cases were still benign 10 years later, and 41.1% (23/56) after an additional decade, while there were 53.8% (162/301) and 59.5% (44/74) respectively in the CDBMS2 group. Conclusions: This 30-year observational study, which is one of the largest published series, indicates that favourable 10-year disability scores of DSS 2 or 3 fail to ensure a long-term benign course of multiple sclerosis. After every decade almost half of the CDBMS were no longer benign. CDBMS, as currently defined, is an unwarranted conceptual hodgepodge. Other criteria using new biomarkers (genetic, biologic or MRI) should be found to detect benign cases of MS.

Clinical implications of benign multiple sclerosis: A 20-year population-based follow-up study

2004 ◽  
Vol 56 (2) ◽  
pp. 303-306 ◽  
Author(s):  
Sean J. Pittock ◽  
Robyn L. McClelland ◽  
William T. Mayr ◽  
Neal W. Jorgensen ◽  
Brian G. Weinshenker ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Population Based ◽  
Clinical Implications ◽  
Follow Up Study ◽  
Benign Multiple Sclerosis

Predictive value of clinical characteristics for ?benign? multiple sclerosis

2007 ◽  
Vol 14 (8) ◽  
pp. 885-889 ◽  
Author(s):  
G. S. M. Ramsaransing ◽  
J. De Keyser
Keyword(s):  
Multiple Sclerosis ◽  
Predictive Value ◽  
Clinical Characteristics ◽  
Benign Multiple Sclerosis

scholarly journals GlobalN-Acetylaspartate Declines Even in Benign Multiple Sclerosis

2010 ◽  
Vol 32 (1) ◽  
pp. 204-209 ◽  
Author(s):  
D.J. Rigotti ◽  
O. Gonen ◽  
R.I. Grossman ◽  
J.S. Babb ◽  
A. Falini ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Benign Multiple Sclerosis
Sign in / Sign up

Export Citation Format

Share Document